



Anja Harder

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Anja Harder
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 1094
Anja.Harder@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

study nurse

Publications (0)

No results found.

Projects (7)

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Clinical Studies - Nov 3, 2023 - Dec 1, 2028

Ongoing

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Clinical Studies - Oct 18, 2023 - Dec 31, 2028

Ongoing

A PHASE IB/II RANDOMIZED, OPEN LABEL DRUG REPURPOSING TRIAL OF GLUTAMATE SIGNALING INHIBITORS IN COMBINATION WITH CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GLUGLIO)

Clinical Studies - May 10, 2023 - Dec 31, 2030

Ongoing

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Clinical Studies - Mar 14, 2023 - Dec 31, 2030

Ongoing

CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study

Clinical Studies - Dec 9, 2022 - Dec 31, 2027

Ongoing

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial

Clinical Studies - Jun 8, 2021 - Dec 31, 2030

Ongoing

TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.

Clinical Studies - Oct 26, 2018 - Dec 31, 2026

Ongoing